Register for our free email digests:
Latest From PaxVax Inc.
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
Likely candidates for use of Gilead's priority review vouchers include GS-4997, a Phase III candidate for NASH, and bictegravir, its second-generation integrase inhibitor for HIV. The virology specialist previously used a PRV successfully to accelerate approval of Odefsey.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Implantable Devices
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- AirXpanders Inc.
- Senior Management
Scott Dodson, Pres. & CEO
Scott Murcray, COO & CFO
Jennie Kim, Sr. Dir., Global Mktg.
Anthony Carnemolla, VP, Sales
Mark Payne, Sr. Dir., R&D
- Contact Info
Phone: (650) 390-9000
1047 Elwell Ct.
Palo Alto, CA 94303
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.